The Metabolic Reprogramming of Immune Cells in the Tumor Microenvironment and the Mechanism of Immune Therapy Resistance
DOI:
https://doi.org/10.54097/60qcx819Keywords:
Immune checkpoint inhibitors, tumor microenvironment, metabolic reprogramming, immunotherapy resistance.Abstract
The efficacy of immune checkpoint inhibitors (ICIs) is often limited by primary and acquired resistance induced by the tumor microenvironment (TME), with the metabolic reprogramming of immune cells being the core mechanism. This review systematically analyzes the three key metabolic stresses in the TME: glucose deprivation, lactate accumulation, and adenosine accumulation. How these metabolic stresses, by reshaping the metabolic states and functions of T cells, macrophages, and dendritic cells, jointly construct an immunosuppressive ecosystem and lead to ICIs resistance. Glucose deprivation directly weakens the activation and function of effector T cells, while lactate and adenosine further inhibit effector immune cells and support the functions of immunosuppressive cells such as regulatory T cells and M2-type macrophages, ultimately forming a treatment-tolerant microenvironment. The article further explores therapeutic strategies targeting metabolic nodes such as lactate dehydrogenase A (LDHA), CD73/CD39 - adenosine axis, to reverse immunosuppression and enhance the efficacy of ICIs, and looks forward to the future direction of using "metabolism-immunity" typing to guide individualized combination therapy.
Downloads
References
[1] A. Ribas, J. D. Wolchok, Cancer immunotherapy using checkpoint blockade. Science. 359, 1350-1355 (2018).
[2] P. Sharma, S. Hu-Lieskovan, J. A. Wargo, A. Ribas, Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 168, 707-723 (2017).
[3] D. O'Sullivan, D. E. Sanin, E. J. Pearce, E. L. Pearce, Metabolic interventions in the immune response to cancer. Nat. Rev. Immunol.19, 324-335 (2019).
[4] C. H. Chang, J. Qiu, D. O'Sullivan, et al., Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 162, 1229-1241 (2015).
[5] P. C. Ho, J. D. Bihuniak, A. N. Macintyre, et al., Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. Cell. 162, 1217-1228 (2015).
[6] B. I. Reinfeld, M. Z. Madden, M. M. Wolf, et al., Cell-programmed nutrient partitioning in the tumour microenvironment. Nature. 593, 282-288 (2021).
[7] A. Angelin, L. Gil-de-Gomez, S. Dahiya, et al., Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments. Cell Metab. 25, 1282-1293 (2017).
[8] O. R. Colegio, N. Q. Chu, A. L. Szabo, et al., Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 513, 559-563 (2014).
[9] M. J. Watson, P. D. A. Vignali, S. J. Mullett, et al., Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature. 591, 645-651 (2021).
[10] S. Kumagai, S. Koyama, K. Itahashi, et al., Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell. 40, 201-218 (2022).
[11] A. Ohta, M. Sitkovsky, Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 414, 916-920 (2001).
[12] B. Allard, D. Allard, L. Buisseret, J. Stagg, The adenosine pathway in immuno-oncology. Nat. Rev. Clin. Oncol. 17, 611-629 (2020).
[13] A. Brand, K. Singer, G. E. Koehl, et al., LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. Cell Metab. 24, 657-671 (2016).
[14] Metabolic regulation of tumor immunity by lactic acid. Nat. Rev. Cancer. 24, 481-499 (2024).
[15] K. Fischer, P. Hoffmann, S. Voelkl, et al., Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 109, 3812-3819 (2007).
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
